The purpose of this study is to determine retrospectively if the application of rivaroxaban after endovenous laser ablation with and without miniphlebectomy is safe and if it lowers the risk of venous thrombosis.
Rivaroxaban is an orally active direct factor Xa inhibitor, that is used for thrombosis prophylaxis for example in the setting of orthopaedic surgery. In the observed situation Rivaroxaban was applied in a dosage of 10mg daily during 5 days after endovenous laser ablation.
Study Type
OBSERVATIONAL
Enrollment
400
University Hospital Basel
Basel, Canton of Basel-City, Switzerland
Number of patients with a EHIT class 3 or class 4 within 6 weeks after endovenous laser ablation
Time frame: within 6 weeks after endovenous laser ablation
Number of major or clinically relevant bleedings within 6 weeks after endovenous laser ablation.
Time frame: within 6 weeks after endovenous laser ablation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.